How do you administer Abciximab?
Abciximab is typically available as an IV solution of 2 mg/ml. Percutaneous coronary intervention (PCI): 0.25 mg/kg IV bolus administered 10 to 60 minutes before the start of PCI followed by infusion of 0.125 mcg/kg/min for 12 hours, not to exceed 10 mcg per minute.
When is Abciximab given?
ReoPro® (abciximab) is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications: in patients undergoing percutaneous coronary intervention.
Is Abciximab still available?
Janssen will no longer have Reopro in the US. The last lot expires September 2019.
Is ReoPro still available?
What are indications for Abciximab?
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned …
What is the half life of Abciximab?
Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.
What is the action of Abciximab?
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules.
What is the half life of abciximab?
Is ReoPro a blood thinner?
ReoPro (abciximab) is a blood thinner used to prevent blood clots during procedures used to open up the blood vessels in the heart (e.g., balloon angioplasty, coronary stent placement, percutaneous coronary intervention-PCI). ReoPro is usually used with heparin and aspirin.
Is Abciximab antiplatelet or anticoagulant?
Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing …
Is abciximab antiplatelet or anticoagulant?
Why was abciximab discontinued?
This stockout is due to an interruption of production at our third-party manufacturing site.” Janssen is advising healthcare professionals to use other glycoprotein IIb/IIIa antagonists while the company works with its “manufacturing partner to evaluate options for returning ReoPro” to the market.